Small cap wrap: TNR Gold, First Phosphate, 374Water, Blockmate

Solis Minerals began diamond drilling at its Cinto Copper Project in Peru, targeting high-priority copper zones. First Phosphate reported strong shareholder support and growth in its registered base. Blockmate Ventures submitted a zoning application for its Wyoming AI data centre. 374Water will showcase its waste destruction technology at WEFTEC 2026. Immunic Inc appointed a new chief data and digital officer. TNR Gold faces a dissident shareholder campaign ahead of its annual meeting.

Original reporting
Published Sep 1, 2026, 3:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 2, 2026, 5:25 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Small cap wrap: TNR Gold, First Phosphate, 374Water, Blockmate — source image
Decision brief

The 30-second read

$PHOSNeutralLow
01

Why it matters

Most items are routine disclosures with limited immediate price impact, except for Ondine Biomedical's Phase 3 success which could drive notable upside.

02

Market read

The wrap provides a snapshot of multiple micro‑cap developments; overall trading relevance is low, with a single high‑impact biotech story.

03

What to watch

Potential regulatory approvals for the biotech product and the execution risk of the data‑centre project could amplify moves if outcomes differ from expectations.

Relevance 4/10Novelty 2/10Timing: today

Background

The article is a small‑cap wrap covering recent corporate updates across mining, biotech, energy, and technology firms.

Company-level read

Ticker impact

$PHOSNeutralHigh confidence
Context

First Phosphate re‑elected its entire board and approved an advance‑notice policy at its AGM.

Expected impact

minimal impact, likely flat trading

Evidence & confidence

Board elections are routine and already priced.

$SCWONeutralHigh confidence
Context

374Water will exhibit its supercritical water oxidation technology at WEFTEC 2026.

Expected impact

likely flat to slight positive bias

Evidence & confidence

Exhibition announcements are informational with low short‑term impact.

$IMUXNeutralHigh confidence
Context

Immunic appointed a chief data and digital officer to lead AI and analytics initiatives.

Expected impact

minimal impact, possibly slight positive sentiment

Evidence & confidence

Management appointments are routine unless tied to major deals.

$CHARBullishMedium confidence
Context

Chariot received a broker target raise and announced a partnership that doubles its Angola footprint.

Expected impact

upward bias from partnership news

Evidence & confidence

Both analyst and operational news can lift small‑cap energy stocks.

Market effects

Aggregated small‑cap updates provide limited sector insight; mining and biotech segments see modest attention.

Primarily North American and European junior markets; no broad regional shift.

Low global relevance; impacts confined to niche investor bases.

Counterpoint

Given the routine nature of most announcements, many may be already priced; focus on the Phase 3 biotech win as the only true catalyst.

Key entities

  • Solis Minerals Ltd

    Mining explorer launching drilling in Peru.

  • First Phosphate Corp.

    Board re‑election and governance update.

  • Blockmate Ventures Inc

    AI data‑centre zoning and Bitcoin mining product launch.

  • 374Water Inc

    Exhibiting supercritical water oxidation tech.

  • Immunic Inc

    Appointed chief data and digital officer.

Related articles

$PHOSMed

First Phosphate Targets 2029 Production as Quebec Project Gains Fast-Track Status

First Phosphate (NASDAQ:PHOS) aims to start production by 2029 after its Quebec project received fast-track status. The company reported a 378% increase in indicated resources, with a 91.1% conversion rate to purified phosphoric acid. It has secured offtake agreements and export-credit support totaling CAD $400 million. The project has a CAD $2.1 billion net present value, a 37% internal rate of return, and a 23-year mine life, according to the company.

$IMUXMedAI 8/10

Immunic to present vidofludimus calcium data at MS conference

Immunic Inc. (IMUX) will present data on vidofludimus calcium at the MSToronto2026 conference. The Phase 2 CALLIPER trial's open-label extension showed trends toward lower disability worsening risk for continuous treatment. Preclinical data suggests neuronal survival benefits. A post-hoc analysis linked reduced EBV-specific T-cell signatures to improved cognitive performance. The drug is in Phase 3 trials for relapsing multiple sclerosis, with results expected by late 2026.

$IMUXMedAI 8/10

Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting

Immunic (IMUX) will present new data on vidofludimus calcium (IMU-838) at MSToronto2026. Four abstracts cover long-term disability outcomes, EBV-related immune activity, cognition, and novel disability measurement. Phase 2 CALLIPER trial data show favorable disability outcomes with continuous treatment. Immunic aims to showcase vidofludimus calcium's potential in multiple sclerosis.

$PHOSMed

Emerging Growth Research Announces New Flash Report on First Phosphate Corp.

Emerging Growth Research released a report on First Phosphate Corp., highlighting potential financing support from Swiss Export Risk Insurance for its Quebec project. The $212.5M support could reduce equity financing needs. First Phosphate is developing a North American supply chain for LFP battery materials, with multiple export credit agency-backed financing sources.

$METAMed

Market movers: Meta, Intel, AMD, Strategy, New

Meta shares rose 12% to $747.91 after strong AI assistant traction and a higher price target from Wells Fargo. New Era Energy secured a 20-year power deal for its Texas data center. Crypto-linked stocks gained as bitcoin surpassed $86,000. Fertilizer producers fell on news of a potential US-Belarus potash deal. Novo Nordisk shares dropped 7% amid competition concerns in the weight-loss drug market. Warner Bros Discovery and Paramount shares rose amid settlement talks.

$PHOSMed

First Phosphate shareholders could see reduced dilution risk, Noble says after SERV news

First Phosphate Corp. (PHOS) may face reduced equity dilution after Noble Capital Markets noted potential lower funding needs for its Bégin-Lamarche project, supported by Swiss Export Risk Insurance (SERV) and other financing. SERV could provide up to US$212.5 million, reducing the equity requirement to about US$82.5 million. Noble maintains an Outperform rating and $25.50 price target.